(Q44338340)

English

Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

0 references

Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

0 references

1 reference

based on heuristic

inferred from title

systolic heart failure

1 reference

based on heuristic

inferred from title

author name string

Xiaojing Wu

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Te Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Qi Zhou

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Shuangfei Li

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Lan Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

31 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

444-453

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Endothelin antagonists in clinical trials: lessons learned

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Long-term use of sildenafil in the therapeutic management of heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology,

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Oxidative stress regulates left ventricular PDE5 expression in the failing heart

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Ventricular tachycardia after administration of sildenafil citrate: a case report

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

PDE5 inhibitors: considerations for preference and long-term adherence

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Nitric oxide inhalation reduces pulmonary tidal volume during exercise in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

21 January 2018

Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and testing of a new measure of health status for clinical trials in heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in hemodynamic parameters and exercise capacity between patients with pulmonary arterial hypertension and chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure

1 reference

https://api.crossref.org/works/10.1002%2FEJHF.47

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/EJHF.47

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44338340&oldid=2109555634"